MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

C3Spectra is pleased to officially announce its approval by the Federal Communications Commission (FCC) as an Automated Frequency Coordination (AFC) operator. This milestone positions the company to ...

Northern Tool + Equipment is bringing the high-octane excitement of Monster Jam® to the Little Rock community. On Thursday, February 20, customers will have the chance to experience the thrill-seeking ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: January 31 at 6:56:02 p.m. EST ...

Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...